Bank of America just raised its EUR/USD forecast
SAN FRANCISCO—Andrew Dudum, CEO of Hims & Hers Health, Inc. (NYSE:HIMS), recently sold 33,513 shares of Class A Common Stock, according to a regulatory filing. The shares were sold on December 2, 2024, at an average price of $33.38 per share, totaling approximately $1.12 million.
The sales were conducted under a Rule 10b5-1 trading plan, which was adopted by Dudum on August 28, 2024. Following the transaction, Dudum holds 33,502 shares directly. Additionally, Dudum maintains indirect ownership of several other stock holdings through various trusts, including the Andrew Dudum 2015 Trust and the AD 2023 GRAT. According to InvestingPro analysis, the company maintains strong financial health with a "GREAT" overall score, and analysts have recently revised earnings estimates upward.
Hims & Hers Health, Inc. is a telehealth company providing a range of health and wellness products and services. The company is headquartered in San Francisco, California.
In other recent news, Hims & Hers Health, Inc. reported robust third-quarter results with a 77% year-over-year increase in sales exceeding $400 million, and an adjusted EBITDA over $50 million. The company also projected Q4 2024 revenue between $465 million and $470 million, marking an 89% to 91% year-over-year increase. In addition, Hims & Hers recently expanded its board of directors with the appointment of Deb Autor, a former deputy commissioner at the FDA. The company also plans to launch liraglutide, the first generic GLP-1, in 2025.
On the analyst front, BofA Securities downgraded Hims & Hers from Buy to Underperform, while TD Cowen, Piper Sandler, and Needham maintained their ratings and raised their price targets. This comes amid potential FDA leadership changes and the agency's stance on GLP-1 compounding, which could impact companies like Hims & Hers.
Furthermore, Hims & Hers showcased a year-over-year subscriber growth of over 40%, with the number of subscribers now utilizing personalized solutions increasing by 175% year-over-year. The company's strategy involving GLP-1s has been effective in retaining customers, highlighting its ability to continue offering compounded personalized GLP-1 solutions.
These are the recent developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.